Silexion Therapeutics Corp Ordinary Shares
SLXNSilexion Therapeutics Corp is a biopharmaceutical company focused on developing innovative therapies for rare and underserved diseases. The company leverages advanced research and development to create targeted treatments with the aim to improve patient outcomes.
Company News
Silexion Therapeutics has initiated GMP clinical manufacturing of SIL204, its next-generation siRNA therapy targeting mutated KRAS in pancreatic cancer, in collaboration with CDMO Catalent at its Limoges, France facility. The company received approval from Tel Aviv Sourasky Medical Center's Helsinki Ethics Committee for its planned Phase 2/3 tria...
Silexion Therapeutics received formal written Scientific Advice from the German Federal Institute for Drugs and Medical Devices regarding its planned Phase 2/3 clinical trial for SIL204, a potential treatment for locally advanced pancreatic cancer. The guidance provides regulatory clarity and supports the company's planned trial initiation in Q2 ...
Silexion Therapeutics reported strong preclinical results for SIL204, a potential cancer therapy targeting KRAS mutations, raised $9.5 million in financing, and remains on track to initiate Phase 2/3 clinical trials in the first half of 2026.
Silexion Therapeutics demonstrated successful systemic distribution of SIL204 to major pancreatic cancer metastatic sites in preclinical studies, showing tumor burden reductions across liver, peritoneum, and lung, with plans to initiate Phase 2/3 trials in H1 2026.
Silexion Therapeutics reported strong preclinical data for SIL204 across multiple KRAS-driven cancer types, demonstrating up to 97% cancer cell inhibition. The company is preparing to initiate Phase 2/3 clinical trials in 2026 and maintains its Nasdaq listing after a reverse stock split.
